INGENUITY CREATES MILESTONES
OF INTELLIGENT MANUFACTURING
The enrollment for clinical trial was successfully completed on January 27, 2021 of Toumai®Laparoscopic Surgical (hereinafter referred to as “Toumai®") of Shanghai Microport Medbot (Group) Co., Ltd. (hereinafter referred to as "Microport® Medbot”), a robotics-specialized subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (hereinafter referred to as “Microport®"), and Toumai® has become the first domestic Laparoscopic Surgical Robot to complete the difficult urological surgeries and the enrollment of patients for multi-center clinical trials in the field of urology. During the enrollment, Toumai® has constantly challenged the difficulty of surgery, and assisted clinical experts in multiple milestone breakthroughs with important clinical value and significance, including the first radical prostatectomy, the first partial nephrectomy and the first partial nephrectomy through retroperitoneal approach with domestic robot, etc., symbolizing that the domestic endoscopic robot independently developed by China has the complex surgical capability and has filled up the gap of domestic intelligent manufacturing of high-end medical devices.
The medical institutions participating in the Toumai® clinical trial project include the First Affiliated Hospital of the Naval Medical University (Shanghai Changhai Hospital), Zhongshan Hospital affiliated to Fudan University, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine and Zhejiang People's Hospital.
Toumai® displays outstanding design concept, system performance, operation and control experience, and so on. Compared with similar imported products, Toumai® has optimized the operator's vision and operation experience, make frequent breakthroughs in clinical application methods, challenged the difficult and complicated urological surgeries, won the recognition and affirmation of experts from various clinical centers, and really created a road of intelligent manufacturing of high-end medical surgical robots in China.
Chao, President of MicroPort®MedBot, said: "Through the joint efforts of experts and teams from various clinical centers, we have successfully completed the enrollment for clinical trials, demonstrating the determination of domestic endoscopic robots to strive for excellence and ingenuity! In the future, MicroPort®MedBot will continue to enhance its cooperation with experts in various clinical application fields across the country, and through innovation-driven technology development, complete rapid iteration and update of products, and provide high-quality and universal intelligent solutions for more doctors and patients. “
-
2024-10-26TOUMAI® SURGICAL ROBOT SYSTEM COMPLETES MULTIPLE LANDMARK ROBOTIC TELESURGERY CASES IN SUB-SAHARA AFRICA IN THE REPUBLIC OF ANGOLA -
2024-10-26Toumai® Achieves South America's First Tele-Surgery Demonstration -
2024-06-26International Orders of Toumai® Robots EXCEED 10 Units! Domestic Surgical Robots Achieve Major Breakthrough in International Commercialization
@Copyright 1998-2023,Shanghai Microport Medbot(Group)Co.,Ltd. All rights reserved.
Website record/ license No.:沪ICP备20013662号
Hu ICP Bei No. 20013662 HGWA Bei No. 31011502015178
Internet Drug Information Service Qualification Certificate No.: (Hu) - Non-operating -2021-0020
The registered trademarks of “微创", "MicroPort" and" 
" are registered trademarks of Shanghai MicroPort Medical (Group) Co., Ltd.” . They have been authorized to be used by Shanghai Microport Medbot (Group) Co., Ltd., and no other party shall use such trademarks without prior written permission thereof.
